The role of low-molecular weight heparins for anticoagulation in pregnant women with mechanical heart valves;Antikoagulation bei schwangeren frauen nach künstlichem herzklappenersatz: 1st niedermolekulares heparin eine alternative?

Zeitschrift fur Kardiologie

Volumn 91, Issue 4, 2002, Pages 297-303

  Leyh, R G ^a   Fischer, Stefan ^a   Ruhparwar, Arjang ^a   Haverich, Axel ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Heart valve replacement; Low molecular weight heparin; Mechanical valve thrombosis; Pregnancy; Warfarin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; DRUG CHOICE; EMBRYOPATHY; FEMALE; GESTATIONAL AGE; HEART VALVE BIOPROSTHESIS; HEPARINIZATION; HUMAN; INTRACARDIAC THROMBOSIS; LUNG EDEMA; MITRAL VALVE PROSTHESIS; MITRAL VALVE REPLACEMENT; PREGNANCY; THROMBOSIS PREVENTION;

ANTICOAGULANTS; BIOPROSTHESIS; FEMALE; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; POSTOPERATIVE COMPLICATIONS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY TRIMESTER, SECOND; PROSTHESIS FAILURE; REOPERATION; RISK; THROMBOSIS;

EID: 0036238010     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003920200030     Document Type: Article

References (50)

1. Low molecular heparin in a pregnant women with heart valve prosthesis
2. AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves
3. A complication in anticoagulation using low-molecular weight heparin in a patient with mechanical valve prosthesis. A case report
4. Cardiac valve prostheses, anticoagulation, and pregnancy
5. Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy a longitudinal safety study
6. Pregnancy in patients with prosthetic heart valves: The effects of anticoagulation on mother, fetus, and neonate
7. Haemostatsis and coagulation disorders in pregnancy
8. Adjusting anticoagulation to prosthesis thrombogenicity and patient risk factors. Recommendations for the Medtronic Hall valve
9. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy
10. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature
11. Pregnancy in patients with prosthetic heart valves: An experience with 45 pregnancies
12. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
13. Coumarin anticoagulation during pregnancy in patients with mechanical valve prostheses
14. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study
15. Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies
16. Guidelines for prevention of thromboembolic events in valvular heart disease
17. Haemostatsis and thrombosis in pregnancy
18. Antiphospholipid antibodies and thrombosis
19. Long term anticoagulation of outpatients with adverse events to oral anticoagulants using low molecular weight heparin
20. Fetal effects of coumadin administered during pregnancy
21. Unexpected findings concerning thromboembolic complications and anticoagulation after complete 10 year follow up of patients with St. Jude Medical prostheses
22. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies
23. Collapse and massive pulmonary edema secondary to thrombosis of a mitral mechanical heart valve prosthesis during low-molecular weight heparin therapy
24. Risks of anticoagulant therapy in pregnant women with artificial heart valves
25. Pregnancy and mechanical valve prostheses: A high-risk situation for the mother and the fetus
26. Anticoagulant therapy in pregnancy: Report of 54 cases
27. Low molecular weight heparin for thromboprophylaxis during pregnancy in 2 patients with mechanical mitral valve replacement
28. Combined use of warfarin and adjusted subcutaneous heparin during pregnancy in patients with an artificial heart valve
29. Low-molecular-weight heparin for prosthetic heart valves: Treatment failure
30. Cardiac valve prostheses, anticoagulation, and pregnancy
31. Prosthetic heart valve and pregnancy: A study of 59 cases
32. Successful anticoagulation with dalteparin in a patient with mechanical heart valves
33. Anticoagulation in pregnant women with mechanical heart valve prostheses
34. Low molecular weight heparin after mechanical heart valve replacement
35. Low molecular weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
36. Problems in the management of patients with artificial valves during pregnancy
37. Pregnancy in patients with prosthetic cardiac valve: A 10-year experience
38. Mechanism of bone and cartilage maldevelopment in the warfarin embryopathy
39. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
40. Acute thrombosis of prosthetic valves: A multivariate analysis of the risk factors for a life threatening event
41. Evolution of blood coagulation activators and inhibitors in the healthy human fetus
42. Anticoagulant therapy in pregnancy
43. The problem of cardiac valve prostheses, anticoagulants, and pregnancy
44. Failure of adjusted dosing of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses
45. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses
46. The hypercoaguable state
47. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves
48. Vitamin K-dependent proteins in the developing and aging nervous system
49. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves
50. Congenital thrombophilia